https://m2.mtmt.hu/ hun 2026-09-21 03:17 JournalArticle 34592029 VALIDATED true Export Date: 2 June 2024 0 false 2026-08-27T09:00:07.830+0000 2024-05-24T08:01:28.036+0000 2024-02-15T15:59:27.590+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Pintér Ibolya Katalin (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2025-09-14T12:32:16.485+0000 2024-05-24T08:01:28.373+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Galambos, Anna Rita true true /api/journal/10056704 REVIEWED BIOMEDICINES 2227-9059 true false 10056704 false 10056704 true 2227-9059 Journal FOREIGN 12 2 421 421 21 2024 The development of opioid tolerance in patients on long-term opioid analgesic treatment is an unsolved matter in clinical practice thus far. Dose escalation is required to restore analgesic efficacy, but at the price of side effects. Intensive research is ongoing to elucidate the underlying mechanisms of opioid analgesic tolerance in the hope of maintaining opioid analgesic efficacy. N-Methyl-D-aspartate receptor (NMDAR) antagonists have shown promising effects regarding opioid analgesic tolerance; however, their use is limited by side effects (memory dysfunction). Nevertheless, the GluN2B receptor remains a future target for the discovery of drugs to restore opioid efficacy. Mechanistically, the long-term activation of µ-opioid receptors (MORs) initiates receptor phosphorylation, which triggers β-arrestin-MAPKs and NOS-GC-PKG pathway activation, which ultimately ends with GluN2B receptor overactivation and glutamate release. The presence of glutamate and glycine as co-agonists is a prerequisite for GluN2B receptor activation. The extrasynaptic localization of the GluN2B receptor means it is influenced by the glycine level, which is regulated by astrocytic glycine transporter 1 (GlyT1). Enhanced astrocytic glycine release by reverse transporter mechanisms as a consequence of high glutamate levels or unconventional MOR activation on astrocytes could further activate the GluN2B receptor. GlyT1 inhibitors might inhibit this condition, thereby reducing opioid tolerance. Funding 2037573 /api/funding/2037573 (FK_138389) false true Funding 2037574 /api/funding/2037574 (TKP2021-EGA-25) false true Funding 2037575 /api/funding/2037575 Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP false true true true 2024 true true true false true false GOLD 2026-08-27 true https://doi.org/10.3390/biomedicines12020421 9 0 9 6 3 9 9 8 9 9 9 6 6 6 3 0 9 6 9 6 0 10 10 Folyóiratcikk Journal Article 24 9 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 3 2 3 2 2025 0 4 2 4 2 2026 0 2 2 2 2 Q1 false false false false 2024-02-22T10:51:58.911+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Orálbiológiai Tanszék (SE / FOK) 7 28 2 7 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 114498723 /api/authorship/114498723 Galambos, Anna Rita [Galambos, Anna Rita (fájdalomkutatás, ...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 1 0.143 true false false Author 10080867 /api/author/10080867 Galambos Anna Rita (fájdalomkutatás, neuropátia, farmakológia) Galambos Anna Rita true true Galambos Anna Rita true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498724 /api/authorship/114498724 Papp, Zsolt Tamás [Papp, Zsolt Tamás (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 2 0.143 false false false Author 10061052 /api/author/10061052 Papp Zsolt Tamás (Farmakológia) Papp Zsolt Tamás true 10061052 true Papp Zsolt Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498725 /api/authorship/114498725 Boldizsár, Imre [Boldizsár Jr, Imre (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 0.143 false false false Author 10096971 /api/author/10096971 Boldizsár Jr Imre (farmakológia) Boldizsár Jr Imre true true Boldizsár Imre true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498726 /api/authorship/114498726 Zádor, Ferenc [Zádor, Ferenc (Opioid receptorok), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 4 0.143 false false false Author 10031135 /api/author/10031135 Zádor Ferenc (Opioid receptorok) Zádor Ferenc true 10031135 true Zádor Ferenc true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498727 /api/authorship/114498727 Köles, László [Köles, László (Farmakológia), szerző] Orálbiológiai Tanszék (SE / FOK) 5 0.143 false false false Author 10015482 /api/author/10015482 Köles László (Farmakológia) Köles László true 10015482 true Köles László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498728 /api/authorship/114498728 Harsing, Laszlo G. ✉ [Hársing, László Gábor (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 6 0.143 false false true Author 10000022 /api/author/10000022 Hársing László Gábor (Farmakológia) Hársing László Gábor true 10000022 true Harsing Laszlo G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114498729 /api/authorship/114498729 Al-Khrasani, Mahmoud ✉ [Al-Khrasani, Mahmoud (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 7 0.143 false true true Author 10015484 /api/author/10015484 Al-Khrasani Mahmoud (Farmakológia) Al-Khrasani Mahmoud true 10015484 true Al-Khrasani Mahmoud true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 25517072 /api/publicationidentifier/25517072 DOI: 10.3390/biomedicines12020421 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/biomedicines12020421 https://doi.org/10.3390/biomedicines12020421 false true PublicationIdentifier 26205647 /api/publicationidentifier/26205647 WoS: 001221204600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001221204600001 https://www.webofscience.com/wos/woscc/full-record/001221204600001 false true PublicationIdentifier 25884470 /api/publicationidentifier/25884470 Scopus: 85187308130 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85187308130 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85187308130 false true PublicationIdentifier 25884469 /api/publicationidentifier/25884469 PubMed: 38398023 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38398023 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38398023&dopt=Abstract false true SjrRating 11443691 /api/sjrrating/11443691 sjr:Q1 (2024) Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) BIOMEDICINES 2227-9059 69 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1301 /api/classificationexternal/1301 Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) true 1301 true Q1 DIRECT true true Reference 50180091 /api/reference/50180091 1. Essmat, N., Karádi, D., Zádor, F., Király, K., Fürst, S., and Al-Khrasani, M. (2023). Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis. Molecules, 28., DOI: 10.3390/molecules28237766 1 10.3390/molecules28237766 false true Reference 50180092 /api/reference/50180092 2. Kiraly 2015: A new potent analgesic agent with reduced liability to produce morphine tolerance., Brain Res. Bull., 117, p. 32, DOI: 10.1016/j.brainresbull.2015.07.005 2 10.1016/j.brainresbull.2015.07.005 false true Reference 50180093 /api/reference/50180093 3. Cahill 2016: Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation., Trends Pharmacol. Sci., 37, p. 963, DOI: 10.1016/j.tips.2016.08.002 3 10.1016/j.tips.2016.08.002 false true Reference 50180094 /api/reference/50180094 4. Kaplovitch, E., Gomes, T., Camacho, X., Dhalla, I.A., Mamdani, M.M., and Juurlink, D.N. (2015). Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. PLoS ONE, 10., DOI: 10.1371/journal.pone.0134550 4 10.1371/journal.pone.0134550 false true Reference 50180095 /api/reference/50180095 5. Hayes 2020: Impact of opioid dose escalation on the development of substance use disorders, accidents, self-inflicted injuries, opioid overdoses and alcohol and non-opioid drug-related overdoses: A retrospective cohort study., Addiction, 115, p. 1098, DOI: 10.1111/add.14940 5 10.1111/add.14940 false true Reference 50180096 /api/reference/50180096 6. Henry 2015: Dose Escalation During the First Year of Long-Term Opioid Therapy for Chronic Pain., Pain Med., 16, p. 733, DOI: 10.1111/pme.12634 6 10.1111/pme.12634 false true Reference 50180097 /api/reference/50180097 7. Chen 2006: Blocking μ opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids., Brain Res., 1081, p. 119, DOI: 10.1016/j.brainres.2006.01.053 7 10.1016/j.brainres.2006.01.053 false true Reference 50180098 /api/reference/50180098 8. Ballantyne 2021: Allostasis theory in opioid tolerance., Pain, 162, p. 2315, DOI: 10.1097/j.pain.0000000000002280 8 10.1097/j.pain.0000000000002280 false true Reference 50180099 /api/reference/50180099 9. Fürst, S., Zádori, Z.S., Zádor, F., Király, K., Balogh, M., László, S.B., Hutka, B., Mohammadzadeh, A., Calabrese, C., and Galambos, A.R. (2020). On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance. Molecules, 25., DOI: 10.3390/molecules25112473 9 10.3390/molecules25112473 false true Reference 50180100 /api/reference/50180100 10. Gong 2016: GluN2B N-methyl-D-aspartate receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after 7 days of morphine administration in rats: Implication for opiate-induced hyperalgesia., Pain, 157, p. 147, DOI: 10.1097/j.pain.0000000000000342 10 10.1097/j.pain.0000000000000342 false true Reference 50180101 /api/reference/50180101 11. Manning 1996: Continuous co-administration of dextromethorphan or MK-801 with morphine: Attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance., Pain, 67, p. 79, DOI: 10.1016/0304-3959(96)81972-5 11 10.1016/0304-3959(96)81972-5 false true Reference 50180102 /api/reference/50180102 12. Trujillo 1991: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801., Science, 251, p. 85, DOI: 10.1126/science.1824728 12 10.1126/science.1824728 false true Reference 50180103 /api/reference/50180103 13. Rutten 2011: Effects of the cognition impairer MK-801 on learning and memory in mice and rats., Behav. Brain Res., 220, p. 215, DOI: 10.1016/j.bbr.2011.01.052 13 10.1016/j.bbr.2011.01.052 false true Reference 50180104 /api/reference/50180104 14. Zhang 2016: Controversies of the Effect of Ketamine on Cognition., Front. Psychiatry, 7, p. 47, DOI: 10.3389/fpsyt.2016.00047 14 10.3389/fpsyt.2016.00047 false true Reference 50180105 /api/reference/50180105 15. Zhou 2021: Molecular mechanisms of opioid tolerance: From opioid receptors to inflammatory mediators (Review)., Exp. Ther. Med., 22, p. 1004, DOI: 10.3892/etm.2021.10437 15 10.3892/etm.2021.10437 false true Reference 50180106 /api/reference/50180106 16. Williams 2013: Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance., Pharmacol. Rev., 65, p. 223, DOI: 10.1124/pr.112.005942 16 10.1124/pr.112.005942 false true Reference 50180107 /api/reference/50180107 17. Lemel, L., Lane, J.R., and Canals, M. (2020). GRKs as Key Modulators of Opioid Receptor Function. Cells, 9., DOI: 10.3390/cells9112400 17 10.3390/cells9112400 false true Reference 50180108 /api/reference/50180108 18. Duarte 2020: Post-translational Modifications of Opioid Receptors., Trends Neurosci., 43, p. 417, DOI: 10.1016/j.tins.2020.03.011 18 10.1016/j.tins.2020.03.011 false true Reference 50180109 /api/reference/50180109 19. Chakrabarti 2020: Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine., J. Neurochem., 152, p. 449, DOI: 10.1111/jnc.14863 19 10.1111/jnc.14863 false true Reference 50180110 /api/reference/50180110 20. Bailey 2006: How important is protein kinase C in μ-opioid receptor desensitization and morphine tolerance?., Trends Pharmacol. Sci., 27, p. 558, DOI: 10.1016/j.tips.2006.09.006 20 10.1016/j.tips.2006.09.006 false true Reference 50180111 /api/reference/50180111 21. Allouche 2014: Opioid receptor desensitization: Mechanisms and its link to tolerance., Front. Pharmacol., 5, p. 280, DOI: 10.3389/fphar.2014.00280 21 10.3389/fphar.2014.00280 false true Reference 50180112 /api/reference/50180112 22. Dang 2012: Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons., Br. J. Pharmacol., 165, p. 1704, DOI: 10.1111/j.1476-5381.2011.01482.x 22 10.1111/j.1476-5381.2011.01482.x false true Reference 50180113 /api/reference/50180113 23. Deng 2019: Mitogen-activated protein kinase signaling mediates opioid-induced presynaptic NMDA receptor activation and analgesic tolerance., J. Neurochem., 148, p. 275, DOI: 10.1111/jnc.14628 23 10.1111/jnc.14628 false true Reference 50180114 /api/reference/50180114 24. Eulenburg, V., and Hülsmann, S. (2022). Synergistic Control of Transmitter Turnover at Glycinergic Synapses by GlyT1, GlyT2, and ASC-1. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23052561 24 10.3390/ijms23052561 false true Reference 50180115 /api/reference/50180115 25. Li, Y., Bao, Y., Zheng, H., Qin, Y., and Hua, B. (2021). Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction. Biomed. Pharmacother., 139., DOI: 10.1016/j.biopha.2021.111653 25 10.1016/j.biopha.2021.111653 false true Reference 50180116 /api/reference/50180116 26. Wong 1986: The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist., Proc. Natl. Acad. Sci. USA, 83, p. 7104, DOI: 10.1073/pnas.83.18.7104 26 10.1073/pnas.83.18.7104 false true Reference 50180117 /api/reference/50180117 27. Mao 1994: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C., J. Neurosci., 14, p. 2301, DOI: 10.1523/JNEUROSCI.14-04-02301.1994 27 10.1523/JNEUROSCI.14-04-02301.1994 false true Reference 50180118 /api/reference/50180118 28. Wong 1996: Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: Binding at μ-opioid receptors., Eur. J. Pharmacol., 297, p. 27, DOI: 10.1016/0014-2999(95)00728-8 28 10.1016/0014-2999(95)00728-8 false true Reference 50180119 /api/reference/50180119 29. Niswender 2010: Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease., Annu. Rev. Pharmacol. Toxicol., 50, p. 295, DOI: 10.1146/annurev.pharmtox.011008.145533 29 10.1146/annurev.pharmtox.011008.145533 false true Reference 50180120 /api/reference/50180120 30. Alexander 2011: G Protein-coupled receptors., Br. J. Pharmacol., 164, p. S5, DOI: 10.1111/j.1476-5381.2011.01649_3.x 30 10.1111/j.1476-5381.2011.01649_3.x false true Reference 50180121 /api/reference/50180121 31. Collingridge 2009: A nomenclature for ligand-gated ion channels., Neuropharmacology, 56, p. 2, DOI: 10.1016/j.neuropharm.2008.06.063 31 10.1016/j.neuropharm.2008.06.063 false true Reference 50180122 /api/reference/50180122 32. Hansen 2018: Structure, function, and allosteric modulation of NMDA receptors., J. Gen. Physiol., 150, p. 1081, DOI: 10.1085/jgp.201812032 32 10.1085/jgp.201812032 false true Reference 50180123 /api/reference/50180123 33. Srivastava 2020: Metabotropic Glutamate Receptors in Alzheimer’s Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future., J. Alzheimer’s Dis., 78, p. 1345, DOI: 10.3233/JAD-201146 33 10.3233/JAD-201146 false true Reference 50180124 /api/reference/50180124 34. Conn 1997: Pharmacology and functions of metabotropic glutamate receptors., Annu. Rev. Pharmacol. Toxicol., 37, p. 205, DOI: 10.1146/annurev.pharmtox.37.1.205 34 10.1146/annurev.pharmtox.37.1.205 false true Reference 50180125 /api/reference/50180125 35. Tamaru 2001: Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites., Neuroscience, 106, p. 481, DOI: 10.1016/S0306-4522(01)00305-0 35 10.1016/S0306-4522(01)00305-0 false true Reference 50180126 /api/reference/50180126 36. Driessen 2019: Vagal Afferent Processing by the Paratrigeminal Nucleus., Front. Physiol., 10, p. 475415, DOI: 10.3389/fphys.2019.01110 36 10.3389/fphys.2019.01110 false true Reference 50180127 /api/reference/50180127 37. Fisher 1996: Comparison of nociceptive effects produced by intrathecal administration of mGluR agonists., NeuroReport, 7, p. 2743, DOI: 10.1097/00001756-199611040-00067 37 10.1097/00001756-199611040-00067 false true Reference 50180128 /api/reference/50180128 38. Fisher 1996: The contribution of metabotropic glutamate receptors (mGluRs) to formalin-induced nociception., Pain, 68, p. 255, DOI: 10.1016/S0304-3959(96)03212-5 38 10.1016/S0304-3959(96)03212-5 false true Reference 50180129 /api/reference/50180129 39. Osikowicz 2013: The glutamatergic system as a target for neuropathic pain relief., Exp. Physiol., 98, p. 372, DOI: 10.1113/expphysiol.2012.069922 39 10.1113/expphysiol.2012.069922 false true Reference 50180130 /api/reference/50180130 40. Chiechio 2016: Modulation of Chronic Pain by Metabotropic Glutamate Receptors., Adv. Pharmacol., 75, p. 63, DOI: 10.1016/bs.apha.2015.11.001 40 10.1016/bs.apha.2015.11.001 false true Reference 50180131 /api/reference/50180131 41. Carlton 2007: Colocalization of metabotropic glutamate receptors in rat dorsal root ganglion cells., J. Comp. Neurol., 501, p. 780, DOI: 10.1002/cne.21285 41 10.1002/cne.21285 false true Reference 50180132 /api/reference/50180132 42. Okubo 2019: Differential expression of mGluRs in rat spinal dorsal horns and their modulatory effects on nocifensive behaviors., Mol. Pain, 15, p. 1744806919875026, DOI: 10.1177/1744806919875026 42 10.1177/1744806919875026 false true Reference 50180133 /api/reference/50180133 43. Haroutunian 2000: Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus., Biol. Psychiatry, 47, p. 22, DOI: 10.1016/S0006-3223(99)00207-3 43 10.1016/S0006-3223(99)00207-3 false true Reference 50180134 /api/reference/50180134 44. Neto 2000: Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat., Brain Res., 854, p. 93, DOI: 10.1016/S0006-8993(99)02326-4 44 10.1016/S0006-8993(99)02326-4 false true Reference 50180135 /api/reference/50180135 45. Muly 2003: Distribution of mGluR1α and mGluR5 immunolabeling in primate prefrontal cortex., J. Comp. Neurol., 467, p. 521, DOI: 10.1002/cne.10937 45 10.1002/cne.10937 false true Reference 50180136 /api/reference/50180136 46. Hernandez 2018: Age-Related Declines in Prefrontal Cortical Expression of Metabotropic Glutamate Receptors that Support Working Memory., eNeuro, 5, p. e0164-18, DOI: 10.1523/ENEURO.0164-18.2018 46 10.1523/ENEURO.0164-18.2018 false true Reference 50180137 /api/reference/50180137 47. Walker 2001: mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia., Neuropharmacology, 40, p. 10, DOI: 10.1016/S0028-3908(00)00114-3 47 10.1016/S0028-3908(00)00114-3 false true Reference 50180138 /api/reference/50180138 48. Valerio 1997: mGluR5 metabotropic glutamate receptor distribution in rat and human spinal cord: A developmental study., Neurosci. Res., 28, p. 49, DOI: 10.1016/S0168-0102(97)01175-9 48 10.1016/S0168-0102(97)01175-9 false true Reference 50180139 /api/reference/50180139 49. Azkue 1997: Distribution of the metabotropic glutamate receptor subtype mGluR5 in rat midbrain periaqueductal grey and relationship with ascending spinofugal afferents., Neurosci. Lett., 228, p. 1, DOI: 10.1016/S0304-3940(97)00357-1 49 10.1016/S0304-3940(97)00357-1 false true Reference 50180140 /api/reference/50180140 50. Palazzo 2019: The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina?., Curr. Neuropharmacol., 18, p. 120, DOI: 10.2174/1570159X17666191001141849 50 10.2174/1570159X17666191001141849 false true Reference 50180141 /api/reference/50180141 51. Govea 2012: Group III metabotropic glutamate receptors and transient receptor potential vanilloid 1 co-localize and interact on nociceptors., Neuroscience, 217, p. 130, DOI: 10.1016/j.neuroscience.2012.05.014 51 10.1016/j.neuroscience.2012.05.014 false true Reference 50180142 /api/reference/50180142 52. Marabese 2005: Differential roles of mGlu8 receptors in the regulation of glutamate and γ-aminobutyric acid release at periaqueductal grey level., Neuropharmacology, 49, p. 157, DOI: 10.1016/j.neuropharm.2005.02.006 52 10.1016/j.neuropharm.2005.02.006 false true Reference 50180143 /api/reference/50180143 53. Karakas 2014: Crystal structure of a heterotetrameric NMDA receptor ion channel., Science, 344, p. 992, DOI: 10.1126/science.1251915 53 10.1126/science.1251915 false true Reference 50180144 /api/reference/50180144 54. Traynelis 2010: Glutamate Receptor Ion Channels: Structure, Regulation, and Function., Pharmacol. Rev., 62, p. 405, DOI: 10.1124/pr.109.002451 54 10.1124/pr.109.002451 false true Reference 50180145 /api/reference/50180145 55. Ko 2008: Cingulate NMDA NR2B receptors contribute to morphine-induced analgesic tolerance., Mol. Brain, 1, p. 2, DOI: 10.1186/1756-6606-1-2 55 10.1186/1756-6606-1-2 false true Reference 50180146 /api/reference/50180146 56. Shimoyama 1996: Oral ketamine produces a dose-dependent CNS depression in the rat., Life Sci., 60, p. PL9, DOI: 10.1016/S0024-3205(96)00592-9 56 10.1016/S0024-3205(96)00592-9 false true Reference 50180147 /api/reference/50180147 57. 2005: The N-Methyl-D-aspartate receptor antagonist dizocilpine inhibits associative antinociceptive tolerance to morphine in mice: Relation with memory., J. Pharmacol. Sci., 97, p. 75, DOI: 10.1254/jphs.FPJ04024X 57 10.1254/jphs.FPJ04024X false true Reference 50180148 /api/reference/50180148 58. Laulin 2002: The Role of Ketamine in Preventing Fentanyl-Induced Hyperalgesia and Subsequent Acute Morphine Tolerance., Obstet. Anesth. Dig., 94, p. 1263 58 false true Reference 50180149 /api/reference/50180149 59. Cabello 1997: Decrease of tolerance to, and physical dependence on morphine by glutamate receptor antagonists., Eur. J. Pharmacol., 332, p. 257, DOI: 10.1016/S0014-2999(97)01099-6 59 10.1016/S0014-2999(97)01099-6 false true Reference 50180150 /api/reference/50180150 60. Elliott 1994: The NMDA Receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids., Pain, 56, p. 69, DOI: 10.1016/0304-3959(94)90151-1 60 10.1016/0304-3959(94)90151-1 false true Reference 50180151 /api/reference/50180151 61. Gutstein 1993: MK-801 inhibits the development of morphine tolerance at spinal sites., Brain Res., 626, p. 332, DOI: 10.1016/0006-8993(93)90597-G 61 10.1016/0006-8993(93)90597-G false true Reference 50180152 /api/reference/50180152 62. Mendez 2008: NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats., Psychopharmacology, 196, p. 497, DOI: 10.1007/s00213-007-0984-8 62 10.1007/s00213-007-0984-8 false true Reference 50180153 /api/reference/50180153 63. Harris 2023: Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model., ACS Chem. Neurosci., 14, p. 917, DOI: 10.1021/acschemneuro.2c00779 63 10.1021/acschemneuro.2c00779 false true Reference 50180154 /api/reference/50180154 64. Paoletti 2013: NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease., Nat. Rev. Neurosci., 14, p. 383, DOI: 10.1038/nrn3504 64 10.1038/nrn3504 false true Reference 50180155 /api/reference/50180155 65. Laurie 1994: Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA., J. Neurosci., 14, p. 3180, DOI: 10.1523/JNEUROSCI.14-05-03180.1994 65 10.1523/JNEUROSCI.14-05-03180.1994 false true Reference 50180156 /api/reference/50180156 66. Tolle 1993: The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray., J. Neurosci., 13, p. 5009, DOI: 10.1523/JNEUROSCI.13-12-05009.1993 66 10.1523/JNEUROSCI.13-12-05009.1993 false true Reference 50180157 /api/reference/50180157 67. Luque 1994: Alternatively spliced isoforms of the N-methyl-d-aspartate receptor subunit 1 are differentially distributed within the rat spinal cord., Neuroscience, 63, p. 629, DOI: 10.1016/0306-4522(94)90510-X 67 10.1016/0306-4522(94)90510-X false true Reference 50180158 /api/reference/50180158 68. Yung 1998: Localization of glutamate receptors in dorsal horn of rat spinal cord., NeuroReport, 9, p. 1639, DOI: 10.1097/00001756-199805110-00069 68 10.1097/00001756-199805110-00069 false true Reference 50180159 /api/reference/50180159 69. Akazawa 1994: Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats., J. Comp. Neurol., 347, p. 150, DOI: 10.1002/cne.903470112 69 10.1002/cne.903470112 false true Reference 50180160 /api/reference/50180160 70. Momiyama 2000: Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord., J. Physiol., 523, p. 621, DOI: 10.1111/j.1469-7793.2000.t01-1-00621.x 70 10.1111/j.1469-7793.2000.t01-1-00621.x false true Reference 50180161 /api/reference/50180161 71. Ma 2000: Localization of N-methyl-d-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats., Neuroscience, 101, p. 699, DOI: 10.1016/S0306-4522(00)00419-X 71 10.1016/S0306-4522(00)00419-X false true Reference 50180162 /api/reference/50180162 72. Wong 2002: Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain., J. Comp. Neurol., 450, p. 303, DOI: 10.1002/cne.10314 72 10.1002/cne.10314 false true Reference 50180163 /api/reference/50180163 73. Wee 2008: Immunolocalization of NMDA receptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cord., J. Comp. Neurol., 509, p. 118, DOI: 10.1002/cne.21747 73 10.1002/cne.21747 false true Reference 50180164 /api/reference/50180164 74. Halassa 2007: The tripartite synapse: Roles for gliotransmission in health and disease., Trends Mol. Med., 13, p. 54, DOI: 10.1016/j.molmed.2006.12.005 74 10.1016/j.molmed.2006.12.005 false true Reference 50180165 /api/reference/50180165 75. Woo 2018: Activation of Astrocytic μ-opioid Receptor Elicits Fast Glutamate Release Through TREK-1-Containing K2P Channel in Hippocampal Astrocytes., Front. Cell. Neurosci., 12, p. 393968, DOI: 10.3389/fncel.2018.00319 75 10.3389/fncel.2018.00319 false true Reference 50180166 /api/reference/50180166 76. Cubelos, B. (2023, December 14). Localización del Transportador de Glicina GLYT1 en Sinapsis Glutamatérgicas y Caracterización de su Interacción con Proteínas Con Dominios PDZ. Available online: https://dialnet.unirioja.es/servlet/tesis?codigo=33450&info=resumen&idioma=SPA. 76 false true Reference 50180167 /api/reference/50180167 77. Scimemi 2004: NR2B-Containing Receptors Mediate Cross Talk among Hippocampal Synapses., J. Neurosci., 24, p. 4767, DOI: 10.1523/JNEUROSCI.0364-04.2004 77 10.1523/JNEUROSCI.0364-04.2004 false true Reference 50180168 /api/reference/50180168 78. Mony 2009: Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential., Br. J. Pharmacol., 157, p. 1301, DOI: 10.1111/j.1476-5381.2009.00304.x 78 10.1111/j.1476-5381.2009.00304.x false true Reference 50180169 /api/reference/50180169 79. Harsing 2006: Glycine Transporter Type-1 and its Inhibitors., Curr. Med. Chem., 13, p. 1017, DOI: 10.2174/092986706776360932 79 10.2174/092986706776360932 false true Reference 50180170 /api/reference/50180170 80. Harsing 2013: Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: The role of synaptic and non-synaptic glycine transporters., Brain Res. Bull., 93, p. 110, DOI: 10.1016/j.brainresbull.2012.12.002 80 10.1016/j.brainresbull.2012.12.002 false true Reference 50180171 /api/reference/50180171 81. Olivares 1997: Analysis of the Transmembrane Topology of the Glycine Transporter GLYT1., J. Biol. Chem., 272, p. 1211, DOI: 10.1074/jbc.272.2.1211 81 10.1074/jbc.272.2.1211 false true Reference 50180172 /api/reference/50180172 82. Raiteri 2010: Functional ‘glial’ GLYT1 glycine transporters expressed in neurons., J. Neurochem., 114, p. 647, DOI: 10.1111/j.1471-4159.2010.06802.x 82 10.1111/j.1471-4159.2010.06802.x false true Reference 50180173 /api/reference/50180173 83. Mohammadzadeh 2019: Glycine transporter inhibitors: A new avenue for managing neuropathic pain., Brain Res. Bull., 152, p. 143, DOI: 10.1016/j.brainresbull.2019.07.008 83 10.1016/j.brainresbull.2019.07.008 false true Reference 50180174 /api/reference/50180174 84. Cioffi, C.L. (2021). Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling. Biomolecules, 11., DOI: 10.3390/biom11060864 84 10.3390/biom11060864 false true Reference 50180175 /api/reference/50180175 85. Łątka, K., and Bajda, M. (2022). Analysis of Binding Determinants for Different Classes of Competitive and Noncompetitive Inhibitors of Glycine Transporters. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23148050 85 10.3390/ijms23148050 false true Reference 50180176 /api/reference/50180176 86. Mohammadzadeh, A., Lakatos, P.P., Balogh, M., Zádor, F., Karádi, D., Zádori, Z.S., Király, K., Galambos, A.R., Barsi, S., and Riba, P. (2021). Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22052479 86 10.3390/ijms22052479 false true Reference 50180177 /api/reference/50180177 87. Evans 2022: Glycinergic Modulation of Pain in Behavioral Animal Models., Front. Pharmacol., 13, p. 860903, DOI: 10.3389/fphar.2022.860903 87 10.3389/fphar.2022.860903 false true Reference 50180178 /api/reference/50180178 88. Li 2018: NMDA Receptor Dependent Long-term Potentiation in Chronic Pain., Neurochem. Res., 44, p. 531, DOI: 10.1007/s11064-018-2614-8 88 10.1007/s11064-018-2614-8 false true Reference 50180179 /api/reference/50180179 89. Toth 1986: Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice., Res. Commun. Psychol. Psychiatry Behav., 11, p. 1 89 false true Reference 50180180 /api/reference/50180180 90. Harsing 2012: Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules—Glycine transporter type 1 and its inhibitors (Review)., Acta Physiol. Hung., 99, p. 1, DOI: 10.1556/APhysiol.99.2012.1.1 90 10.1556/APhysiol.99.2012.1.1 false true Reference 50180181 /api/reference/50180181 91. Zhang 2009: The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine., J. Physiol., 587, p. 3207, DOI: 10.1113/jphysiol.2009.168757 91 10.1113/jphysiol.2009.168757 false true Reference 50180182 /api/reference/50180182 92. Carland 2013: Oleoyl-l-carnitine inhibits glycine transport by GlyT2., Br. J. Pharmacol., 168, p. 891, DOI: 10.1111/j.1476-5381.2012.02213.x 92 10.1111/j.1476-5381.2012.02213.x false true Reference 50180183 /api/reference/50180183 93. Brown 2001: Discovery and SAR of Org 24598—A Selective Glycine Uptake Inhibitor., Bioorganic Med. Chem. Lett., 11, p. 2007, DOI: 10.1016/S0960-894X(01)00355-9 93 10.1016/S0960-894X(01)00355-9 false true Reference 50180184 /api/reference/50180184 94. Herdon 2001: Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes., Neuropharmacology, 41, p. 88, DOI: 10.1016/S0028-3908(01)00043-0 94 10.1016/S0028-3908(01)00043-0 false true Reference 50180185 /api/reference/50180185 95. Harsing 2013: An overview of Glyt-1 inhibitors under evaluation for the treatment of schizophrenia., Drugs Future, 38, p. 555, DOI: 10.1358/dof.2013.38.8.1965101 95 10.1358/dof.2013.38.8.1965101 false true Reference 50180186 /api/reference/50180186 96. Gilfillan 2009: Glycine transporters and their inhibitors., Top. Med. Chem., 4, p. 223, DOI: 10.1007/7355_2009_030 96 10.1007/7355_2009_030 false true Reference 50180187 /api/reference/50180187 97. McBain 1989: Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes., Mol. Pharmacol., 36, p. 556 97 false true Reference 50180188 /api/reference/50180188 98. Lee, M.-Y., Lin, Y.-R., Tu, Y.-S., Tseng, Y.J., Chan, M.-H., and Chen, H.-H. (2017). Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials. J. Biomed. Sci., 24., DOI: 10.1186/s12929-016-0314-8 98 10.1186/s12929-016-0314-8 false true Reference 50180189 /api/reference/50180189 99. Werdehausen 2012: Lidocaine Metabolites Inhibit Glycine Transporter 1., Anesthesiology, 116, p. 147, DOI: 10.1097/ALN.0b013e31823cf233 99 10.1097/ALN.0b013e31823cf233 false true Reference 50180190 /api/reference/50180190 100. Long 2006: Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain., Brain Res. Bull., 69, p. 626, DOI: 10.1016/j.brainresbull.2006.03.007 100 10.1016/j.brainresbull.2006.03.007 false true Reference 50180191 /api/reference/50180191 101. Watson 1990: d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed inXenopus oocytes., Brain Res., 510, p. 158, DOI: 10.1016/0006-8993(90)90745-W 101 10.1016/0006-8993(90)90745-W false true Reference 50180192 /api/reference/50180192 102. Harrison 1998: Stimulatory effects of opioids., Br. J. Anaesth., 81, p. 20, DOI: 10.1093/bja/81.1.20 102 10.1093/bja/81.1.20 false true Reference 50180193 /api/reference/50180193 103. Corkrum, M., Rothwell, P.E., Thomas, M.J., Kofuji, P., and Araque, A. (2019). Opioid-Mediated Astrocyte–Neuron Signaling in the Nucleus Accumbens. Cells, 8., DOI: 10.3390/cells8060586 103 10.3390/cells8060586 false true Reference 50180194 /api/reference/50180194 104. Geerlings 2001: Glycine neurotransmitter transporters: An update., Mol. Membr. Biol., 18, p. 13, DOI: 10.1080/09687680010028762 104 10.1080/09687680010028762 false true Reference 50180195 /api/reference/50180195 105. Sato 1995: Modulation of a Recombinant Glycine Transporter (GLYT1b) by Activation of Protein Kinase C., J. Neurochem., 65, p. 1967, DOI: 10.1046/j.1471-4159.1995.65051967.x 105 10.1046/j.1471-4159.1995.65051967.x false true Reference 50180196 /api/reference/50180196 106. Xie 2009: A Receptor Mechanism for Methamphetamine Action in Dopamine Transporter Regulation in Brain., J. Pharmacol. Exp. Ther., 330, p. 316, DOI: 10.1124/jpet.109.153775 106 10.1124/jpet.109.153775 false true Reference 50180197 /api/reference/50180197 107. Miller 2011: The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity., J. Neurochem., 116, p. 164, DOI: 10.1111/j.1471-4159.2010.07109.x 107 10.1111/j.1471-4159.2010.07109.x false true Reference 50180198 /api/reference/50180198 108. Hanuska 2016: Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions., Neurochem. Res., 41, p. 73, DOI: 10.1007/s11064-015-1713-z 108 10.1007/s11064-015-1713-z false true Reference 50180199 /api/reference/50180199 109. Gledhill 2021: Synthesis of the Mechanisms of Opioid Tolerance: Do We Still Say NO?., Cell. Mol. Neurobiol., 41, p. 927, DOI: 10.1007/s10571-021-01065-8 109 10.1007/s10571-021-01065-8 false true Reference 50180200 /api/reference/50180200 110. Ibuki 2003: Spinal amino acid release and repeated withdrawal in spinal morphine tolerant rats., Br. J. Pharmacol., 138, p. 689, DOI: 10.1038/sj.bjp.0705102 110 10.1038/sj.bjp.0705102 false true Reference 50180201 /api/reference/50180201 111. Cortese, K., Gagliani, M.C., and Raiteri, L. (2023). Interactions between Glycine and Glutamate through Activation of Their Transporters in Hippocampal Nerve Terminals. Biomedicines, 11., DOI: 10.3390/biomedicines11123152 111 10.3390/biomedicines11123152 false true Reference 50180202 /api/reference/50180202 112. Raiteri 2005: Glycine taken up through GLYT1 and GLYT2 heterotransporters into glutamatergic axon terminals of mouse spinal cord elicits release of glutamate by homotransporter reversal and through anion channels., Biochem. Pharmacol., 69, p. 159, DOI: 10.1016/j.bcp.2004.08.029 112 10.1016/j.bcp.2004.08.029 false true Reference 50180203 /api/reference/50180203 113. Zhao 2012: Chronic Opioid Potentiates Presynaptic but Impairs Postsynaptic N-Methyl-d-aspartic Acid Receptor Activity in Spinal Cords: Implications for opioid hyperalgesia and tolerance., J. Biol. Chem., 287, p. 25073, DOI: 10.1074/jbc.M112.378737 113 10.1074/jbc.M112.378737 false true Reference 50180204 /api/reference/50180204 114. Sánchez-Blázquez, P., Rodríguez-Muñoz, M., and Garzón, J. (2010). Mu-Opioid Receptors Transiently Activate the Akt-nNOS Pathway to Produce Sustained Potentiation of PKC-Mediated NMDAR-CaMKII Signaling. PLoS ONE, 5., DOI: 10.1371/journal.pone.0011278 114 10.1371/journal.pone.0011278 false true Reference 50180205 /api/reference/50180205 115. Marques 2020: Neurobiology of glycine transporters: From molecules to behavior., Neurosci. Biobehav. Rev., 118, p. 97, DOI: 10.1016/j.neubiorev.2020.07.025 115 10.1016/j.neubiorev.2020.07.025 false true Reference 50180206 /api/reference/50180206 116. Javitt 1991: Recent advances in the phencyclidine model of schizophrenia., Am. J. Psychiatry, 148, p. 1301, DOI: 10.1176/ajp.148.10.1301 116 10.1176/ajp.148.10.1301 false true Reference 50180207 /api/reference/50180207 117. Chang 2014: NMDA Pathology and Treatment of Schizophrenia., Curr. Pharm. Des., 20, p. 5118, DOI: 10.2174/1381612819666140110121908 117 10.2174/1381612819666140110121908 false true Reference 50180208 /api/reference/50180208 118. Javitt 1999: Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors., Biol. Psychiatry, 45, p. 668, DOI: 10.1016/S0006-3223(98)00237-6 118 10.1016/S0006-3223(98)00237-6 false true Reference 50180209 /api/reference/50180209 119. Adell, A. (2020). Brain NMDA Receptors in Schizophrenia and Depression. Biomolecules, 10., DOI: 10.3390/biom10060947 119 10.3390/biom10060947 false true Reference 50180210 /api/reference/50180210 120. Pei 2021: Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients with Schizophrenia., Front. Psychiatry, 12, p. 742058, DOI: 10.3389/fpsyt.2021.742058 120 10.3389/fpsyt.2021.742058 false true Reference 50180211 /api/reference/50180211 121. Rosenbrock 2023: Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia., Eur. Arch. Psychiatry Clin. Neurosci., 273, p. 1557, DOI: 10.1007/s00406-023-01576-z 121 10.1007/s00406-023-01576-z false true Reference 50180212 /api/reference/50180212 122. Dang 2014: Targeting of NMDA Receptors in the Treatment of Major Depression., Curr. Pharm. Des., 20, p. 5151, DOI: 10.2174/1381612819666140110120435 122 10.2174/1381612819666140110120435 false true Reference 50180213 /api/reference/50180213 123. Newell 1997: Glycine Causes Increased Excitability and Neurotoxicity by Activation of NMDA Receptors in the Hippocampus., Exp. Neurol., 145, p. 235, DOI: 10.1006/exnr.1997.6463 123 10.1006/exnr.1997.6463 false true Reference 50180214 /api/reference/50180214 124. Ghasemi 2011: The NMDA receptor complex as a therapeutic target in epilepsy: A review., Epilepsy Behav., 22, p. 617, DOI: 10.1016/j.yebeh.2011.07.024 124 10.1016/j.yebeh.2011.07.024 false true Reference 50180215 /api/reference/50180215 125. Ugale, V., Deshmukh, R., Lokwani, D., Reddy, P.N., Khadse, S., Chaudhari, P., and Kulkarni, P.P. (2023). GluN2B subunit selective N-methyl-D-aspartate receptor ligands: Democratizing recent progress to assist the development of novel neurotherapeutics. Mol. Divers., 1–28., DOI: 10.1007/s11030-023-10656-0 125 10.1007/s11030-023-10656-0 false true Reference 50180216 /api/reference/50180216 126. Berman 2000: Antidepressant effects of ketamine in depressed patients., Biol. Psychiatry, 47, p. 351, DOI: 10.1016/S0006-3223(99)00230-9 126 10.1016/S0006-3223(99)00230-9 false true Reference 50180217 /api/reference/50180217 127. Choudhury 2021: Ketamine: Neuroprotective or Neurotoxic?., Front. Neurosci., 15, p. 672526, DOI: 10.3389/fnins.2021.672526 127 10.3389/fnins.2021.672526 false true Reference 50180218 /api/reference/50180218 128. Myslobodsky 1981: Ketamine: Convulsant or anti-convulsant?., Pharmacol. Biochem. Behav., 14, p. 27, DOI: 10.1016/0091-3057(81)90099-X 128 10.1016/0091-3057(81)90099-X false true Reference 50180219 /api/reference/50180219 129. Pinto 2015: Glycine transporters type 1 inhibitor promotes brain preconditioning against NMDA-induced excitotoxicity., Neuropharmacology, 89, p. 274, DOI: 10.1016/j.neuropharm.2014.10.003 129 10.1016/j.neuropharm.2014.10.003 false true Reference 50180220 /api/reference/50180220 130. Shen 2015: Glycine transporter 1 is a target for the treatment of epilepsy., Neuropharmacology, 99, p. 554, DOI: 10.1016/j.neuropharm.2015.08.031 130 10.1016/j.neuropharm.2015.08.031 false true /api/publication/34592029 Galambos Anna Rita et al. Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance. (2024) BIOMEDICINES 2227-9059 12 2<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10080867"><a href="/gui2/?type=authors&mode=browse&sel=10080867" target="_blank">Galambos Anna Rita (<span class="authorship-author-name">Galambos Anna Rita</span> <span class="authorAux-mtmt"> fájdalomkutatás, neuropátia, farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10061052"><a href="/gui2/?type=authors&mode=browse&sel=10061052" target="_blank">Papp Zsolt Tamás (<span class="authorship-author-name">Papp Zsolt Tamás</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10096971"><a href="/gui2/?type=authors&mode=browse&sel=10096971" target="_blank">Boldizsár Imre (<span class="authorship-author-name">Boldizsár Jr Imre</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10031135"><a href="/gui2/?type=authors&mode=browse&sel=10031135" target="_blank">Zádor Ferenc (<span class="authorship-author-name">Zádor Ferenc</span> <span class="authorAux-mtmt"> Opioid receptorok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015482"><a href="/gui2/?type=authors&mode=browse&sel=10015482" target="_blank">Köles László (<span class="authorship-author-name">Köles László</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000022"><a href="/gui2/?type=authors&mode=browse&sel=10000022" target="_blank">Harsing Laszlo G. ✉ (<span class="authorship-author-name">Hársing László Gábor</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015484"><a href="/gui2/?type=authors&mode=browse&sel=10015484" target="_blank">Al-Khrasani Mahmoud ✉ (<span class="authorship-author-name">Al-Khrasani Mahmoud</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34592029" target="_blank">Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance</a></div> <div> <span class="journal-title">BIOMEDICINES</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2227-9059">2227-9059</a>)</span>: <span class="journal-volume">12</span> <span class="journal-issue">2</span> <span class="page"> Paper 421. 21 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/biomedicines12020421" target="_blank" href="https://doi.org/10.3390/biomedicines12020421"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001221204600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001221204600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85187308130" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85187308130"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38398023" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38398023&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 9</span> | Független: 6 | Függő: 3 | Nem jelölt: 0 | WoS jelölt: 8 | Scopus jelölt:&nbsp;9 | WoS/Scopus jelölt:&nbsp;9 | DOI jelölt:&nbsp;9 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34592029&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 10 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34592029</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (FK_138389), (TKP2021-EGA-25), Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP </div> <div class="lastModified">Utolsó módosítás: 2024.05.24. 10:01 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 2 June 2024</pre> </div></div>